Skip to main content
Premium Trial:

Request an Annual Quote

NCI's Protein Interaction Group, Cell Therapeutics Unit Ink CRADA for Targeted Cancer Rxs

NEW YORK (GenomeWeb News) — Systems Medicine, a wholly owned subsidiary of Cell Therapeutics, has penned a Cooperative Research and Development Agreement with the National Cancer Institute to develop targeted cancer drugs, Cell Therapeutics said today.
 
Specifically, the five-year alliance calls for the companies to research human monoclonal antibodies, peptides, and small molecules that affect signal transduction through the insulin-like growth factor receptor type I and the insulin receptor.
 
Terms of the deal call for Systems Medicine to have an exclusive option to elect an exclusive or non-exclusive commercialization license to any inventions developed under the agreement. Scientists at Systems Medicine and parent Cell Therapeutics will work with researchers of the NCI’s Protein Interaction Group.
 
If the research is “successful,” Cell Therapeutics would have “exclusive rights to negotiate with NIH for a product that targets the ligand that activates the IGF receptor, unlike current approaches to IGF inhibition that target the receptor directly," James Bianco, president and CEO of Cell Therapeutics, said in a statement.
 
Financial terms of the agreement were not disclosed.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.